Clinical efficacy and safety of low﹣dose decitabine subcutaneous injection combined with arsenicals in treatment of medium﹣and high﹣risk myelodysplastic syndromes
10.3760/cma.j.issn.1009﹣9921.2019.07.003
- VernacularTitle:低剂量地西他滨皮下注射联合砷剂治疗中高危骨髓增生异常综合征效果及安全性观察
- Author:
Ruihua MI
1
;
Lin CHEN
;
Ling CHEN
;
Qingsong YIN
;
Fangfang YUAN
;
Mengjuan LI
;
Xudong WEI
Author Information
1. 郑州大学附属肿瘤医院血液科 450008
- Keywords:
Myelodysplastic syndromes;
Decitabine;
Injections,subcutaneous;
Arsenite;
Treatment outcome;
Adverse reactions
- From:
Journal of Leukemia & Lymphoma
2019;28(7):396-400
- CountryChina
- Language:Chinese
-
Abstract:
Objective To explore the clinical efficacy and safety of low﹣dose decitabine subcutaneous injection combined with arsenicals in the treatment of medium﹣ and high﹣risk myelodysplastic syndromes (MDS). Methods Eight cases of medium﹣ and high﹣risk MDS without allogeneic hematopoietic stem cell transplantation in the Affiliated Cancer Hospital of Zhengzhou University and Xinhua Area Hospital of Pingdingshan City from January 2015 to August 2018 were retrospectively analyzed. The patients were given subcutaneous injection of low﹣dose decitabine combined with arsenicals. The specific regimen was as follow:0.1-0.2 mg/kg of decitabine, subcutaneous injection 2 times/week, 4 weeks in total; arsenic injection 10 mg/time or 0.16 mg/kg, intravenous administration, 1 time/d, 4 weeks; compound Huangdai tablets 60 mg/kg per day, 3 times orally. The efficacy and adverse reactions were observed. Results In 8 patients, there were 5 male and 3 female, with an average age of 61.4 years old (44-80 years old) Eleven cases were refractory anemia with excess blasts (RAEB), 6 cases were RAEB﹣2, 1 case was refractory cytopenia with multilineage dysplasia (RCMD) with bone marrow fibrosis (MF). Three of the patients had previously received treatment with decitabine. All patients completed the treatment successfully and no treatment﹣related deaths occurred. By the end of follow﹣up, 2 patients had complete remission, 4 patients had complete bone marrow remission with hematologic improvement, 1 patient had stable disease, and 1 patient had disease progression. For 2 patients who had been treated with decitabine regimen, the regimen of re﹣administered decitabine plus arsenic was still effective. Eight patients had more than level 2 of myelosuppression, except for one patient with intestinal infection due to unclean diet and one patient with mild pulmonary infection. The remaining 6 patients had no associated infection and heart, liver, kidney and other adverse reactions. Conclusion Low﹣dose decitabine subcutaneous injection combined with arsenicals is safe and could be a new treatment for the medium﹣ and high﹣risk MDS.
